Stephen J. Demarest, Ph.D. - Publications

2000 Stony Brook University, Stony Brook, NY, United States 

40 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Toughiri R, Wu X, Ruiz D, Huang F, Crissman JW, Dickey M, Froning K, Conner EM, Cujec TP, Demarest SJ. Comparing domain interactions within antibody Fabs with kappa and lambda light chains. Mabs. 0. PMID 27454112 DOI: 10.1080/19420862.2016.1214785  1
2016 Leaver-Fay A, Froning KJ, Atwell S, Aldaz H, Pustilnik A, Lu F, Huang F, Yuan R, Hassanali S, Chamberlain AK, Fitchett JR, Demarest SJ, Kuhlman B. Computationally Designed Bispecific Antibodies using Negative State Repertoires. Structure (London, England : 1993). PMID 26996964 DOI: 10.1016/j.str.2016.02.013  1
2015 Wu X, Sereno AJ, Huang F, Lewis SM, Lieu RL, Weldon C, Torres C, Fine C, Batt MA, Fitchett JR, Glasebrook AL, Kuhlman B, Demarest SJ. Fab-based bispecific antibody formats with robust biophysical properties and biological activity. Mabs. 7: 470-82. PMID 25774965 DOI: 10.1080/19420862.2015.1022694  1
2015 Wu X, Sereno AJ, Huang F, Zhang K, Batt M, Fitchett JR, He D, Rick HL, Conner EM, Demarest SJ. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies. Mabs. 7: 364-76. PMID 25611120 DOI: 10.1080/19420862.2015.1007826  1
2014 Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, Hansen-Estruch C, Chamberlain AK, Truhlar SM, Conner EM, Atwell S, ... ... Demarest SJ, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nature Biotechnology. 32: 191-8. PMID 24463572 DOI: 10.1038/nbt.2797  1
2014 Clark LA, Demarest SJ, Eldredge J, Jarpe MB, Li Y, Simon K, van Vlijmen HW. Influence of canonical structure determining residues on antibody affinity and stability. Journal of Structural Biology. 185: 223-7. PMID 23994046 DOI: 10.1016/j.jsb.2013.08.009  1
2014 Demarest SJ, Frasca V. Differential Scanning Calorimetry in the Biopharmaceutical Sciences Biophysical Characterization of Proteins in Developing Biopharmaceuticals. 287-306. DOI: 10.1016/B978-0-444-59573-7.00011-7  1
2013 Demarest SJ, Gardner J, Vendel MC, Ailor E, Szak S, Huang F, Doern A, Tan X, Yang W, Grueneberg DA, Richards EJ, Endege WO, Harlow E, Koopman LA. Evaluation of Tyro3 expression, Gas6-mediated Akt phosphorylation, and the impact of anti-Tyro3 antibodies in melanoma cell lines. Biochemistry. 52: 3102-18. PMID 23570341 DOI: 10.1021/bi301588c  1
2013 Proctor EA, Kota P, Demarest SJ, Caravella JA, Dokholyan NV. Highly covarying residues have a functional role in antibody constant domains. Proteins. 81: 884-95. PMID 23280585 DOI: 10.1002/prot.24247  1
2013 Proctor EA, Kota P, Demarest SJ, Caravella JA, Dokholyan NV. Metric to distinguish closely related domain families using sequence information. Journal of Molecular Biology. 425: 475-8. PMID 23219465 DOI: 10.1016/j.jmb.2012.11.031  1
2012 Vendel MC, Favis M, Snyder WB, Huang F, Capili AD, Dong J, Glaser SM, Miller BR, Demarest SJ. Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties. Archives of Biochemistry and Biophysics. 526: 188-93. PMID 22230329 DOI: 10.1016/  1
2011 Demarest SJ, Hariharan K, Dong J. Emerging antibody combinations in oncology. Mabs. 3: 338-51. PMID 21697653  1
2011 Houde D, Demarest SJ. Fine details of IGF-1R activation, inhibition, and asymmetry determined by associated hydrogen /deuterium-exchange and peptide mass mapping. Structure (London, England : 1993). 19: 890-900. PMID 21645859 DOI: 10.1016/j.str.2011.03.014  1
2011 Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, Boccia A, Virata C, Gamez J, Yco G, Favis M, ... ... Demarest SJ, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. Mabs. 3: 273-88. PMID 21393993 DOI: 10.4161/mabs.3.3.15188  1
2011 Dong J, Sereno A, Snyder WB, Miller BR, Tamraz S, Doern A, Favis M, Wu X, Tran H, Langley E, Joseph I, Boccia A, Kelly R, Wortham K, Wang Q, ... ... Demarest SJ, et al. Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. The Journal of Biological Chemistry. 286: 4703-17. PMID 21123183 DOI: 10.1074/jbc.M110.184317  1
2010 Dong J, Demarest SJ, Sereno A, Tamraz S, Langley E, Doern A, Snipas T, Perron K, Joseph I, Glaser SM, Ho SN, Reff ME, Hariharan K. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Molecular Cancer Therapeutics. 9: 2593-604. PMID 20716637 DOI: 10.1158/1535-7163.MCT-09-1018  1
2010 Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS, Glaser SM. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Engineering, Design & Selection : Peds. 23: 549-57. PMID 20457695 DOI: 10.1093/protein/gzq028  1
2010 Demarest SJ, Hariharan M, Elia M, Salbato J, Jin P, Bird C, Short JM, Kimmel BE, Dudley M, Woodnutt G, Hansen G. Neutralization of Clostridium difficile toxin A using antibody combinations. Mabs. 2: 190-8. PMID 20150758 DOI: 10.4161/mabs.2.2.11220  1
2009 Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, Farrington GK, Lugovskoy A, Joseph I, Bailly V, Wang X, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. Mabs. 1: 128-41. PMID 20061822 DOI: 10.4161/mabs.1.2.7631  1
2009 Jordan JL, Arndt JW, Hanf K, Li G, Hall J, Demarest S, Huang F, Wu X, Miller B, Glaser S, Fernandez EJ, Wang D, Lugovskoy A. Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules. Proteins. 77: 832-41. PMID 19626705 DOI: 10.1002/prot.22502  1
2009 Miller BR, Glaser SM, Demarest SJ. Rapid screening platform for stabilization of scFvs in Escherichia coli. Methods in Molecular Biology (Clifton, N.J.). 525: 279-89, xiv. PMID 19252856 DOI: 10.1007/978-1-59745-554-1_14  1
2009 Doern A, Cao X, Sereno A, Reyes CL, Altshuler A, Huang F, Hession C, Flavier A, Favis M, Tran H, Ailor E, Levesque M, Murphy T, Berquist L, Tamraz S, ... ... Demarest SJ, et al. Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo. The Journal of Biological Chemistry. 284: 10254-67. PMID 19211557 DOI: 10.1074/jbc.M809709200  1
2009 Wang N, Smith WF, Miller BR, Aivazian D, Lugovskoy AA, Reff ME, Glaser SM, Croner LJ, Demarest SJ. Conserved amino acid networks involved in antibody variable domain interactions. Proteins. 76: 99-114. PMID 19089973 DOI: 10.1002/prot.22319  1
2008 Demarest SJ, Glaser SM. Antibody therapeutics, antibody engineering, and the merits of protein stability. Current Opinion in Drug Discovery & Development. 11: 675-87. PMID 18729019  1
2007 Garber E, Demarest SJ. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochemical and Biophysical Research Communications. 355: 751-7. PMID 17321501 DOI: 10.1016/j.bbrc.2007.02.042  1
2006 Demarest SJ, Hopp J, Chung J, Hathaway K, Mertsching E, Cao X, George J, Miatkowski K, LaBarre MJ, Shields M, Kehry MR. An intermediate pH unfolding transition abrogates the ability of IgE to interact with its high affinity receptor FcepsilonRIalpha. The Journal of Biological Chemistry. 281: 30755-67. PMID 16905745 DOI: 10.1074/jbc.M605190200  1
2006 Demarest SJ, Chen G, Kimmel BE, Gustafson D, Wu J, Salbato J, Poland J, Elia M, Tan X, Wong K, Short J, Hansen G. Engineering stability into Escherichia coli secreted Fabs leads to increased functional expression. Protein Engineering, Design & Selection : Peds. 19: 325-36. PMID 16672248 DOI: 10.1093/protein/gzl016  1
2005 Demarest SJ, Salbato J, Elia M, Zhong J, Morrow T, Holland T, Kline K, Woodnutt G, Kimmel BE, Hansen G. Structural characterization of the cell wall binding domains of Clostridium difficile toxins A and B; evidence that Ca2+ plays a role in toxin A cell surface association. Journal of Molecular Biology. 346: 1197-206. PMID 15713474 DOI: 10.1016/j.jmb.2004.12.059  1
2004 Demarest SJ, Deechongkit S, Dyson HJ, Evans RM, Wright PE. Packing, specificity, and mutability at the binding interface between the p160 coactivator and CREB-binding protein. Protein Science : a Publication of the Protein Society. 13: 203-10. PMID 14691235 DOI: 10.1110/ps.03366504  1
2004 Demarest SJ, Rogers J, Hansen G. Optimization of the antibody C(H)3 domain by residue frequency analysis of IgG sequences. Journal of Molecular Biology. 335: 41-8. PMID 14659738 DOI: 10.1016/j.jmb.2003.10.040  1
2003 Horng JC, Demarest SJ, Raleigh DP. pH-dependent stability of the human alpha-lactalbumin molten globule state: contrasting roles of the 6 - 120 disulfide and the beta-subdomain at low and neutral pH. Proteins. 52: 193-202. PMID 12833543 DOI: 10.1002/prot.10406  1
2002 Demarest SJ, Chung J, Dyson HJ, Wright PE. Assignment of a 15 kDa protein complex formed between the p160 coactivator ACTR and CREB binding protein. Journal of Biomolecular Nmr. 22: 377-8. PMID 12018488 DOI: 10.1023/A:1014988325241  1
2002 Demarest SJ, Martinez-Yamout M, Chung J, Chen H, Xu W, Dyson HJ, Evans RM, Wright PE. Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. Nature. 415: 549-53. PMID 11823864 DOI: 10.1038/415549a  1
2001 Demarest SJ, Zhou SQ, Robblee J, Fairman R, Chu B, Raleigh DP. A comparative study of peptide models of the alpha-domain of alpha-lactalbumin, lysozyme, and alpha-lactalbumin/lysozyme chimeras allows the elucidation of critical factors that contribute to the ability to form stable partially folded states. Biochemistry. 40: 2138-47. PMID 11329282 DOI: 10.1021/bi001975z  1
2001 Demarest SJ, Horng JC, Raleigh DP. A protein dissection study demonstrates that two specific hydrophobic clusters play a key role in stabilizing the core structure of the molten globule state of human alpha-lactalbumin. Proteins. 42: 237-42. PMID 11119648 DOI: 10.1002/1097-0134(20010201)42:2<237::AID-PROT110>3.0.CO;2-B  1
2000 Demarest SJ, Raleigh DP. Solution structure of a peptide model of a region important for the folding of alpha-lactalbumin provides evidence for the formation of nonnative structure in the denatured state. Proteins. 38: 189-96. PMID 10656265 DOI: 10.1002/(SICI)1097-0134(20000201)38:2<189::AID-PROT7>3.0.CO;2-F  1
2000 Moriarty DF, Demarest SJ, Robblee J, Fairman R, Raleigh DP. Local interactions and the role of the 6-120 disulfide bond in alpha-lactalbumin: implications for formation of the molten globule state. Biochimica Et Biophysica Acta. 1476: 9-19. PMID 10606762 DOI: 10.1016/S0167-4838(99)00219-8  1
1999 Demarest SJ, Boice JA, Fairman R, Raleigh DP. Defining the core structure of the alpha-lactalbumin molten globule state. Journal of Molecular Biology. 294: 213-21. PMID 10556040 DOI: 10.1006/jmbi.1999.3228  1
1999 Demarest SJ, Hua Y, Raleigh DP. Local interactions drive the formation of nonnative structure in the denatured state of human alpha-lactalbumin: a high resolution structural characterization of a peptide model in aqueous solution. Biochemistry. 38: 7380-7. PMID 10353850 DOI: 10.1021/bi990320z  1
1998 Demarest SJ, Fairman R, Raleigh DP. Peptide models of local and long-range interactions in the molten globule state of human alpha-lactalbumin. Journal of Molecular Biology. 283: 279-91. PMID 9761690 DOI: 10.1006/jmbi.1998.2099  1
Show low-probability matches.